BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Navigenics Raises $18 Million in Series C Financing


2/3/2010 6:55:17 AM

Bookmark and Share

FOSTER CITY, Calif.--(BUSINESS WIRE)--Navigenics, a leading personal genomics company, announced today that the company has raised approximately $18 million of funding. The Procter and Gamble Company, with a worldwide portfolio of leading consumer brands, has joined existing Navigenics investors Kleiner Perkins Caufield and Byers and Mohr Davidow Ventures who also participated in this financing round.

“I welcome the partnership of Procter and Gamble. Their extraordinary track record of consumer understanding provides Navigenics with an unparalleled opportunity to understand and serve the needs of our customers,” said Vance Vanier, MD, Navigenics President and CEO. “When combined with their commitment to developing innovative consumer health and wellness products and an expanding focus on health services, P&G’s insight and brand will strengthen Navigenics’ position to embed personal genomics into the prevention dialogue of everyday health care.”

“Navigenics represents an exciting opportunity for future innovation for P&G,” said Nathan Estruth, Vice President of Procter & Gamble FutureWorks and Board member of MDVIP, a national network of primary care physicians focused on personalized, preventive care. MDVIP has initiated a collaborative effort with Navigenics, making their genetic test available as a service to MDVIP-affiliated physicians. “Based on their strong science and clinical foundation, Navigenics promises to change the shape of health care as we know it. Personalized genetic testing can have significant meaning in helping consumers focused on prevention and wellness live better, healthier lives – something that P&G has always been committed to.”

“This Series C financing will help ensure that Navigenics has the ability to continue our groundbreaking research into the impact of genomics on preventive health care, expand our clinical offerings into exciting new areas and lead the way in making personal genomics an integral part of employer-sponsored preventive health and wellness programs,” said Dr. Vanier.

ABOUT NAVIGENICS

Navigenics, Inc. is a privately held company based in Foster City, Calif. The company was founded by David Agus, M.D. and Dietrich Stephan, Ph.D., with the goal of improving health outcomes in individuals across the population. Navigenics educates and empowers individuals and their physicians with knowledge of their genetic predispositions, and then motivates them to act on the information to prevent the onset of disease, achieve earlier diagnosis, appropriately manage disease, or otherwise lessen its impact. Navigenics’ lead investors are Kleiner Perkins Caufield and Byers and Mohr Davidow Ventures. More information can be found at www.navigenics.com.

Contact:

Navigenics, Inc. Brenna Sweeney, 650-585-7523 bsweeney@navigenics.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->